Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial - Schmid, Peter; Schneeweiss, Andreas (The lancet. Oncology, 2020)
Available online 27 November 2019